WO2002057436A3 - Red blood cell from a transgenic animal as vehicle for polypeptide delivery - Google Patents

Red blood cell from a transgenic animal as vehicle for polypeptide delivery Download PDF

Info

Publication number
WO2002057436A3
WO2002057436A3 PCT/GB2002/000169 GB0200169W WO02057436A3 WO 2002057436 A3 WO2002057436 A3 WO 2002057436A3 GB 0200169 W GB0200169 W GB 0200169W WO 02057436 A3 WO02057436 A3 WO 02057436A3
Authority
WO
WIPO (PCT)
Prior art keywords
red blood
blood cell
polypeptide
transgenic animal
vehicle
Prior art date
Application number
PCT/GB2002/000169
Other languages
French (fr)
Other versions
WO2002057436A2 (en
Inventor
Anthony Patrick Mchale
Roger Kingdon Craig
Original Assignee
Gendel Ltd
Anthony Patrick Mchale
Kingdon Craig R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0101469A external-priority patent/GB0101469D0/en
Priority claimed from US09/785,802 external-priority patent/US20020151004A1/en
Priority claimed from GB0105631A external-priority patent/GB0105631D0/en
Priority claimed from PCT/GB2001/003327 external-priority patent/WO2002007752A2/en
Application filed by Gendel Ltd, Anthony Patrick Mchale, Kingdon Craig R filed Critical Gendel Ltd
Priority to AU2002219391A priority Critical patent/AU2002219391A1/en
Publication of WO2002057436A2 publication Critical patent/WO2002057436A2/en
Publication of WO2002057436A3 publication Critical patent/WO2002057436A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

We disclose a method of producing a red blood cell suitable for delivery of a polypeptide to a vertebrate, the method comprising the steps of: providing a transgenic animal carrying and expressing a transgene encoding the polypeptide; obtaining a red blood cell containing the polypeptide from the animal; and sensitising the red blood cell. A method of producing a polypeptide by isolating a red blood cell from a transgenic animal carrying and expressing a transgene encoding the polypeptide, sensitizing the red blood cell, exposing the red blood cells to an energy source sufficient to disrupt the sensitized red blood cell, and isolating the polypeptide, is also disclosed. We also disclose an assay for determining delivery of an agent to a target site.
PCT/GB2002/000169 2001-01-19 2002-01-16 Red blood cell from a transgenic animal as vehicle for polypeptide delivery WO2002057436A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002219391A AU2002219391A1 (en) 2001-01-19 2002-01-16 Red blood cell from a transgenic animal as vehicle for polypeptide delivery

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
GB0101469.5 2001-01-19
GB0101469A GB0101469D0 (en) 2001-01-19 2001-01-19 Polypeptide Delivery
US26480801P 2001-01-29 2001-01-29
US60/264,808 2001-01-29
GB0100417 2001-02-01
GBPCT/GB01/00417 2001-02-01
US09/785,802 US20020151004A1 (en) 2000-07-24 2001-02-16 Delivery vehicles and methods for using the same
US09/785,802 2001-02-16
GB0105631.6 2001-03-07
GB0105631A GB0105631D0 (en) 2001-03-07 2001-03-07 Assays for agent delivery
US27980301P 2001-03-29 2001-03-29
US60/279,803 2001-03-29
PCT/GB2001/003327 WO2002007752A2 (en) 2000-07-24 2001-07-24 Red blood cell as vehicle for agent-membrane translocation sequence conjugate
GBPCT/GB01/03327 2001-07-24

Publications (2)

Publication Number Publication Date
WO2002057436A2 WO2002057436A2 (en) 2002-07-25
WO2002057436A3 true WO2002057436A3 (en) 2003-09-04

Family

ID=27562582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000169 WO2002057436A2 (en) 2001-01-19 2002-01-16 Red blood cell from a transgenic animal as vehicle for polypeptide delivery

Country Status (1)

Country Link
WO (1) WO2002057436A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9364565B2 (en) 2000-03-15 2016-06-14 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
KR101803099B1 (en) 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 Antibodies and processes for preparing the same
EP2303245B1 (en) * 2008-07-11 2016-12-28 ETH Zurich Degradable microcapsules
ES2525411T3 (en) 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method to prepare them
JP5812861B2 (en) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． MYC modifier, method of using the MYC modifier, and method of identifying agents that modulate MYC
EP3868387A1 (en) 2012-07-20 2021-08-25 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2018102678A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
WO2020252297A1 (en) * 2019-06-14 2020-12-17 The University Of North Carolina At Chapel Hill Photoactive compositions for therapuetic agent delivery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652449A (en) * 1982-07-05 1987-03-24 Centre National De La Recherche Scientifique (Cnrs) Encapsulating biological active substances into erythrocytes
US5766884A (en) * 1989-09-26 1998-06-16 The Uab Research Foundation Synthesis of functional human hemoglobin and other proteins in erythroid tissues of transgenic animals
WO2000007630A1 (en) * 1998-07-31 2000-02-17 Gendel Limited Nucleic acid delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652449A (en) * 1982-07-05 1987-03-24 Centre National De La Recherche Scientifique (Cnrs) Encapsulating biological active substances into erythrocytes
US5766884A (en) * 1989-09-26 1998-06-16 The Uab Research Foundation Synthesis of functional human hemoglobin and other proteins in erythroid tissues of transgenic animals
WO2000007630A1 (en) * 1998-07-31 2000-02-17 Gendel Limited Nucleic acid delivery

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SCOTT M D ET AL: "CHEMICAL CAMOUFLAGE OF ANTIGENIC DETERMINANTS: STEALTH ERYTHROCYTES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, July 1997 (1997-07-01), pages 7566 - 7571, XP002915147, ISSN: 0027-8424 *
SHARMA A. ET AL.: "High-efficiency synthesis of human alpha-endorphin and magainin in the erythrocytes of transgenic mice: A production system for therapeutic peptides.", PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 9337 - 9341, XP002230834 *
SUTHERLAND H.G.E. ET AL.: "A globin enhancer acts by increasing the proportion of erythrocytes expressing a linked transgene", MOLECULAR AND CELLULAR BIOLOGY, vol. 17, no. 3, 1997, pages 1607 - 1614, XP002230835 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9364565B2 (en) 2000-03-15 2016-06-14 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same

Also Published As

Publication number Publication date
WO2002057436A2 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
WO2002057436A3 (en) Red blood cell from a transgenic animal as vehicle for polypeptide delivery
Littlewood-Evans et al. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry
SU1701111A3 (en) Method of pyrazoloic[3,4-@]pyrimidines preparation
WO2001096915A3 (en) Microfabrication of organic optical elements
FI20085733A (en) Methods for treating disease using Sertoli cells and allografts or xenografts
WO2002031134A3 (en) Novel serine protease genes related to dppiv
ATE382638T1 (en) METHODS FOR PRODUCING GLYCOSYLATED ANTIBODIES AND ANTIBODY FRAGMENTS WITH REACTIVE KETONE GROUPS
WO2001035990A3 (en) Method for enhancing t cell reactivity toward tumour antigens
ATE416489T1 (en) METHOD AND ITS DEVICE FOR IMPROVING THE EFFICIENCY AND PREVENTING THE DECOMPOSITION OF THIS ENERGY STORAGE DEVICE
WO2005030939A3 (en) Method and composition for regulating expansion of stem cells
DE60331101D1 (en) ANTIBODY AGAINST DAMAGED TISSUE
WO2002068635A3 (en) Methods of inhibiting expression of a target gene in mammalian cells
WO2005094355A3 (en) Methods for altering protein production rates
JP2004516020A5 (en)
Salet et al. Effects of photodynamic action on energy coupling of Ca2+ uptake in liver mitochondria
DE60214127D1 (en) HYBRIDOMY CELL LINE G250 AND ITS USE FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES
EP1559318A4 (en) Transgenic mammal carrying ganp gene transferred thereinto and utilization thereof
EP0348494B1 (en) Dioxetanes for use in assays
BR0014926A (en) Protein production system
WO2005048925A3 (en) Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
Schultheiss et al. Hormonal regulation of the skin diffusional permeability to water during development and metamorphosis of Xenopus laevis Daudin
AU2003293237A1 (en) Methods for reacting an antigen masking compound with red blood cells with high efficiency
EA200600704A1 (en) IMMOBILIZATION OF BIO-CATALYST
WO2005121178A3 (en) Immunoaffinity chromatography polyol-responsive monoclonal antibodies
AU2002225011A1 (en) Method for improving the water balance of fuel cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP